Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
- PMID: 15931259
- DOI: 10.1038/nrd1752
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab
Abstract
Immunologists have long hypothesized that particular 'molecular addresses' govern lymphocyte entry to a given organ. In 1992, alpha4beta1 integrin was identified as the key molecule involved in homing to inflamed regions of the brain. An antibody to alpha4beta1integrin blocked paralysis in an animal model of multiple sclerosis, and the humanized monoclonal antibody natalizumab, which binds alpha4beta1 integrin, reduced relapses 66% in clinical trials in multiple sclerosis. Three months after its expedited approval by the FDA, natalizumab was removed from the market after two cases of deadly progressive multifocal leukoencephalopathy were reported among the few thousand patients who had taken this drug in those clinical trials.
Similar articles
-
Natalizumab: targeting alpha4-integrins in multiple sclerosis.Neurodegener Dis. 2008;5(1):16-22. doi: 10.1159/000109933. Neurodegener Dis. 2008. PMID: 18075270 Review.
-
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.Expert Rev Neurother. 2004 Jul;4(4):571-80. doi: 10.1586/14737175.4.4.571. Expert Rev Neurother. 2004. PMID: 15853576 Review.
-
Multiple sclerosis and Natalizumab.Am J Ther. 2007 Nov-Dec;14(6):555-60. doi: 10.1097/MJT.0b013e31804bfa6a. Am J Ther. 2007. PMID: 18090880
-
Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.Neurol Res. 2006 Apr;28(3):291-8. doi: 10.1179/016164106X98189. Neurol Res. 2006. PMID: 16687056 Review.
-
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.Curr Opin Neurol. 2006 Aug;19(4):341-9. doi: 10.1097/01.wco.0000236612.66839.a2. Curr Opin Neurol. 2006. PMID: 16914971 Review.
Cited by
-
Multiple sclerosis and drug discovery: A work of translation.EBioMedicine. 2021 Jun;68:103392. doi: 10.1016/j.ebiom.2021.103392. Epub 2021 May 24. EBioMedicine. 2021. PMID: 34044219 Free PMC article. Review.
-
Targeted delivery of complexes of biotin-PEG-polyethylenimine and NF-kappaB decoys to brain-derived endothelial cells in vitro.Pharm Res. 2008 Mar;25(3):605-15. doi: 10.1007/s11095-007-9389-y. Epub 2007 Oct 20. Pharm Res. 2008. PMID: 17952570
-
Nuanced roles of cytokines in three major human brain disorders.J Clin Invest. 2008 Nov;118(11):3557-63. doi: 10.1172/JCI36532. J Clin Invest. 2008. PMID: 18982162 Free PMC article. Review.
-
Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation.Stem Cell Res Ther. 2015 Dec 10;6:245. doi: 10.1186/s13287-015-0222-y. Stem Cell Res Ther. 2015. PMID: 26651832 Free PMC article.
-
The therapeutic potential of bone marrow-derived macrophages in neurological diseases.CNS Neurosci Ther. 2022 Dec;28(12):1942-1952. doi: 10.1111/cns.13964. Epub 2022 Sep 6. CNS Neurosci Ther. 2022. PMID: 36066198 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical